Respiratory Syncytial Virus Glycoprotein F Antibody (11-2-F3), Alexa Fluor™ 350, Novus Biologicals™

Catalog No.	Quantity
NP20412A30	0.1 mL

Catalog No. NP20412A30 Supplier Novus Biologicals Supplier No. NBP250412AF350

Description

Mouse Monoclonal Antibody

Respiratory Syncytial Virus Glycoprotein F Monoclonal specifically detects Respiratory Syncytial Virus Glycoprotein F in Virus samples. It is validated for Western Blot, ELISA, Immunocytochemistry/Immunofluorescence.

Specifications

• Antigen: Respiratory Syncytial Virus Glycoprotein F
• Applications: Western Blot, ELISA, Immunocytochemistry, Immunofluorescence
• Classification: Monoclonal
• Clone: 11-2-F3
• Conjugate: Alexa Fluor 350
• Dilution: Western Blot, ELISA, Immunocytochemistry/Immunofluorescence
• Formulation: 50 mM sodium borate with 0.05% sodium azide
• Host Species: Mouse
• Immunogen: Gradient-purified RSF-44 virus (subgroup A) UV inactivated for 20 minutes at 20C
• Purification Method: Protein A purified
• Quantity: 0.1 mL
• Research Discipline: Virology Bacteria and Parasites
• Primary or Secondary: Primary
• Test Specificity: This antibody reacts with the RS virus fusion glycoprotein F (also named VP70 or F0 protein), specifically to a subunit of the F protein, F1 (also named VGP48 or 48kDa), from both subgroups A and B of RS virus.This antibody has a high neutralising activity; 90% plaque neutralization titre of 102.2 (Gimenez et al 1996). This property makes it potentially useful for the preparation of reagents for prevention and/or therapeutic use (for example, vaccines or new-generation of man-made antibodies). The characterisation of the epitope of this antibody which induce high neutralising activity will be useful for the preparation of reagents (for example vaccine) to prevent RS virus infection. A RS virus vaccine is not yet available. A vaccine could be used to increase the maternal immunity to RS virus, which would then be passed to the newborn baby to provide passive immunity.The further characterisation of the epitope recognised by this antibody, which possesses a high neutralising activity, will be useful for the preparation of reagents to prevent RS virus infection. New-generation man-made antibodies, based on the 11-2-F3 antibody, could complement the effectiveness of polivizumab (Synagis), which is used to prevent but not treat established RS virus infections (Nature Biotechnology, 2013, 31, 952).
• Target Species: Virus
• Content And Storage: Store at 4°C in the dark.
• Isotype: IgG1